Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cambridge Laboratories Group has announced that Xenazine, the first and only product for the treatment of chorea associated with Huntington's disease, has received approval from the FDA.
Subscribe to our email newsletter
The announcement follows the FDA’s peripheral and central nervous system drugs advisory committee’s unanimous decision in December 2007 to recommend Xenazine for approval.
Cambridge owns the worldwide rights to Xenazine and licensed the US and Canadian rights to Prestwick Pharmaceuticals in 2002 and 2004 respectively. The drug is marketed as Nitoman in Canada and is approved for the treatment of various hyperkinetic movement disorders, including chorea associated with Huntington’s disease.
Xenazine will be distributed in the US by Cambridge’s partner Prestwick Pharmaceuticals.
Mark Evans, CEO of Cambridge Laboratories, said: “We look forward to working with our marketing partner Prestwick to drive Xenazine’s success as it enters the key US market place.”